A method of treating skin by reducing tumor necrosis factor alpha (TNF-) activity or matrix metalloproteinase enzyme (MMP-1) activity in a person's skin is disclosed. The method can include topically applying a composition that includes an effective amount of an extract of Brachychiton acerifolius to the person's skin to reduce TNF- activity or MMP-1 activity in the skin.

This invention concerns an enhanced green tea based product for oral use whereby the nutritional and health benefits of green tea, and additives which shall include some combination of flavoring, preservatives, caffeine, humectants, and water, can be ingested and absorbed by the user.

This invention concerns an enhanced green tea based product for oral use whereby the nutritional and health benefits of green tea, and additives which shall include some combination of flavoring, preservatives, caffeine, humectants, and water, can be ingested and absorbed by the user.

This invention concerns an enhanced green tea based product for oral use whereby the nutritional and health benefits of green tea, and additives which shall include some combination of flavoring, preservatives, caffeine, humectants, and water, can be ingested and absorbed by the user.

Disclosed is method of treating skin by reducing TNF-a production in a person's skin in need of treatment, the method comprising topically applying a composition that includes an effective amount of an aqueous extract of Syzygium moorei leaf to the person's skin, wherein TNF-a production in the skin is reduced.

Disclosed is method of treating skin by reducing TNF-a production in a person's skin in need of treatment, the method comprising topically applying a composition that includes an effective amount of an aqueous extract of Syzygium moorei leaf to the person's skin, wherein TNF-a production in the skin is reduced.

Disclosed is method of treating skin by reducing TNF-a production in a person's skin in need of treatment, the method comprising topically applying a composition that includes an effective amount of an aqueous extract of Syzygium moorei leaf to the person's skin, wherein TNF-a production in the skin is reduced.

Provided are processes of reducing and/or eliminating risk factors associated with metabolic syndrome in a subject through the administration of a nelumbo extract. The nelumbo extract supplement is administered orally, intravenously, or subcutaneously. In one aspect, a daily dose of 10-1,000 mg of the extract supplement is administered to the subject for a period of 6 weeks to 6 months.

Provided are processes of reducing and/or eliminating risk factors associated with metabolic syndrome in a subject through the administration of a nelumbo extract. The nelumbo extract supplement is administered orally, intravenously, or subcutaneously. In one aspect, a daily dose of 10-1,000 mg of the extract supplement is administered to the subject for a period of 6 weeks to 6 months.

The present invention relates to a composition comprising: extract of flowers, leaves, roots and/or seeds of Nelumbo nucifera; Saccharomyces, preferably selected from S. cerevisiae and S. boulardii; Bacillus coagulans; mineral salts; group B and C vitamins; optionally garlic, optionally taurine. The use of said composition in the prevention and/or treatment of the dysmetabolic syndrome is also claimed.